BACKGROUND: Congenital myasthenic syndromes (CMSs) are characterized by hypotonia, episodic apnea, muscle weakness, ptosis and generalized fatigability. CMS type 20 (CMS20) is a rare disorder caused by variants in SLC5A7. In contrast to most other CMSs, CMS20 is also associated with neurodevelopmental disorders (NDDs). Only 19 patients from 14 families have been reported so far. METHODS: We studied a 12-year-old boy with symptoms manifested at six weeks of age. Later, he also showed speech delay, moderate intellectual disability and autism. Analysis of CMS genes known at the time of clinical diagnosis yielded no results. Trio exome sequencing (ES) was performed. RESULTS: ES revealed compound heterozygosity for two SLC5A7 variants, p.(Asn431Lys) and p.(Ile291Thr). While the first variant was absent from all databases, the second variant has already been described in one patient. In silico analysis of known pathogenic SLC5A7 variants showed that variants with a higher predicted deleteriousness may be associated with earlier onset and increased severity of neuromuscular manifestations. CONCLUSION: Our patient confirms that CMS20 can be associated with NDDs. The study illustrates the strength of ES in deciphering the genetic basis of rare diseases, contributes to characterization of CMS20 and suggests trends in genotype-phenotype correlation in CMS20.

Department of Biology and Medical Genetics Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Pediatric Neurology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Pediatrics and Adolescent Medicine Diagnostic and Research Unit for Rare Diseases Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Department of Statistics and Probability Faculty of Informatics and Statistics University of Economics Prague Czech Republic

Zobrazit více v PubMed

Banerjee, M. , Arutyunov, D. , Brandwein, D. , Janetzki‐Flatt, C. , Kolski, H. , Hume, S. , Leonard, N. J. , Watt, J. , Lacson, A. , Baradi, M. , Leslie, E. M. , Cordat, E. , & Caluseriu, O. (2019). The novel p.Ser263Phe mutation in the human high‐affinity choline transporter 1 (CHT1/SLC5A7) causes a lethal form of fetal akinesia syndrome. Human Mutation, 40, 1676–1683. 10.1002/humu.23828 PubMed DOI

Barwick, K. E. , Wright, J. , Al‐Turki, S. , McEntagart, M. M. , Nair, A. , Chioza, B. , Al‐Memar, A. , Modarres, H. , Reilly, M. M. , Dick, K. J. , Ruggiero, A. M. , Blakely, R. D. , Hurles, M. E. , & Crosby, A. H. (2012). Defective presynaptic choline transport underlies hereditary motor neuropathy. American Journal of Human Genetics, 91, 1103–1107. 10.1016/j.ajhg.2012.09.019 PubMed DOI PMC

Bauché, S. , O'Regan, S. , Azuma, Y. , Laffargue, F. , McMacken, G. , Sternberg, D. , Brochier, G. , Buon, C. , Bouzidi, N. , Topf, A. , Lacène, E. , Remerand, G. , Beaufrere, A. M. , Pebrel‐Richard, C. , Thevenon, J. , El Chehadeh‐Djebbar, S. , Faivre, L. , Duffourd, Y. , Ricci, F. , … Nicole, S. (2016). Impaired presynaptic high‐afinity choline transporter causes a congenital myasthenic syndrome with episodic apnea. American Journal of Human Genetics, 99, 753–761. 10.1016/j.ajhg.2016.06.033 PubMed DOI PMC

McMacken, G. , Whittaker, R. G. , Evangelista, T. , Abicht, A. , Dusl, M. , & Lochmüller, H. (2018). Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long‐term follow‐up of 19 patients. Journal of Neurology, 265, 194–203. PubMed PMC

Okuda, T. , Haga, T. , Kanai, Y. , Endou, H. , Ishihara, T. , & Katsura, I. (2000). Identification and characterization of the high‐affinity choline transporter. Nature Neuroscience, 3, 120–125. 10.1038/72059 PubMed DOI

Pardal‐Fernández, J. M. , Carrascosa‐Romero, M. C. , Álvarez, S. , Medina‐Monzón, M. C. , Caamaño, M. B. , & de Cabo, C. (2018). A new severe mutation in the SLC5A7 gene related to congenital myasthenic syndrome type 20. Neuromuscular Disorders, 28, 881–884. 10.1016/j.nmd.2018.06.020 PubMed DOI

Rodríguez Cruz, P. M. , Hughes, I. , Manzur, A. , Munot, P. , Ramdas, S. , Wright, R. , Breen, C. , Pitt, M. , Pagnamenta, A. T. , Taylor, J. C. , Palace, J. , & Beeson, D. (2021). Presynaptic congenital myasthenic syndrome due to three novel mutations in SLC5A7 encoding the sodium‐dependant high‐affinity choline transporter. Neuromuscular Disorders, 31, 21–28. 10.1016/j.nmd.2020.10.006 PubMed DOI

Rodríguez Cruz, P. M. , Palace, J. , & Beeson, D. (2018). The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes. International Journal of Molecular Sciences, 19(6), 1677. 10.3390/ijms19061677 PubMed DOI PMC

Thompson, R. , Bonne, G. , Missier, P. , & Lochmüller, H. (2019). Targeted therapies for congenital myasthenic syndromes: Systematic review and steps towards a treatabolome. Emerging Topics in Life Sciences, 3(1), 19–37. 10.1042/ETLS20180100 PubMed DOI PMC

Wang, H. , Salter, C. G. , Refai, O. , Hardy, H. , Barwick, K. E. S. , Akpulat, U. , Kvarnung, M. , Chioza, B. A. , Harlalka, G. , Taylan, F. , Sejersen, T. , Wright, J. , Zimmerman, H. H. , Karakaya, M. , Stüve, B. , Weis, J. , Schara, U. , Russell, M. A. , Abdul‐Rahman, O. A. , … Crosby, A. H. (2017). Choline transporter mutations in severe congenital myasthenic syndrome disrupt transporter localization. Brain, 140, 2838–2850. 10.1093/brain/awx249 PubMed DOI PMC